USE OF NKP46 FOR PREVENTING DIABETES

Ofer Mandelboim; Angel Porgador; Yaakov Naparstek; Chamutal Gur

USE OF NKP46 FOR PREVENTING DIABETES

Ofer Mandelboim (Inventor), Angel Porgador (Inventor), Yaakov Naparstek (Inventor), Chamutal Gur (Inventor)

The Shraga Segal Department of Microbiology, Immunology and Genetics

Research output: Patent

Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Original language	English
Patent number	US2012076753
IPC	A61P 37/ 02 A I
Priority date	18/03/10
State	Published - 29 Mar 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{3a580bf9d23d417fba2086bbb369baa2,

title = "USE OF NKP46 FOR PREVENTING DIABETES",

abstract = "The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.",

author = "Ofer Mandelboim and Angel Porgador and Yaakov Naparstek and Chamutal Gur",

year = "2012",

month = mar,

day = "29",

language = "English",

type = "Patent",

note = "US2012076753; A61P 37/ 02 A I",

}

TY - PAT

T1 - USE OF NKP46 FOR PREVENTING DIABETES

AU - Mandelboim, Ofer

AU - Porgador, Angel

AU - Naparstek, Yaakov

AU - Gur, Chamutal

PY - 2012/3/29

Y1 - 2012/3/29

N2 - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

AB - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

M3 - Patent

M1 - US2012076753

ER -

USE OF NKP46 FOR PREVENTING DIABETES

Abstract

UN SDGs

Fingerprint

Cite this